| Literature DB >> 28923916 |
Yida Jiang1, Xianchai Lin1, Zhongshu Tang1, Chunsik Lee1, Geng Tian2, Yuxiang Du1, Xiangke Yin1, Xiangrong Ren1, Lijuan Huang1, Zhimin Ye1, Wei Chen1, Fan Zhang3, Jia Mi2, Zhiqin Gao4, Shasha Wang1, Qishan Chen1, Liying Xing1, Bin Wang5, Yihai Cao6,7,8, William C Sessa9,10, Rong Ju11, Yizhi Liu11, Xuri Li11.
Abstract
Ocular neovascularization is a devastating pathology of numerous ocular diseases and is a major cause of blindness. Caveolin-1 (Cav-1) plays important roles in the vascular system. However, little is known regarding its function and mechanisms in ocular neovascularization. Here, using comprehensive model systems and a cell permeable peptide of Cav-1, cavtratin, we show that Cav-1 is a critical player in ocular neovascularization. The genetic deletion of Cav-1 exacerbated and cavtratin administration inhibited choroidal and retinal neovascularization. Importantly, combined administration of cavtratin and anti-VEGF-A inhibited neovascularization more effectively than monotherapy, suggesting the existence of other pathways inhibited by cavtratin in addition to VEGF-A. Indeed, we found that cavtratin suppressed multiple critical components of pathological angiogenesis, including inflammation, permeability, PDGF-B and endothelial nitric oxide synthase expression (eNOS). Mechanistically, we show that cavtratin inhibits CNV and the survival and migration of microglia and macrophages via JNK. Together, our data demonstrate the unique advantages of cavtratin in antiangiogenic therapy to treat neovascular diseases.Entities:
Keywords: angiogenesis; caveolin-1; cavtratin; inflammation; ocular neovascularization
Mesh:
Substances:
Year: 2017 PMID: 28923916 PMCID: PMC5635880 DOI: 10.1073/pnas.1706394114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205